The introduction of antibody-based biologics, mainly tumor necrosis factor-α (TNF-α) inhibitors, has revolutionized the outcomes of IBD therapy, although many patients remain unresponsive or lose the response during treatment. Here, TNF is linked to inflammatory bowel disease.